Using Fast Field-Cycling Imaging to Monitor Kidney Disease
Investigating a Novel Molecular Imaging Technique, Fast Field-Cycling, for Kidney Health and Disease
This study is testing a new imaging technique to see if it can better tell the difference between healthy kidneys and those with disease in people who are already being checked for kidney problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Aberdeen Academic / other |
| Locations | 1 site (Aberdeen) |
| Trial ID | NCT05851417 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the effectiveness of Fast Field-Cycling (FFC) imaging in distinguishing healthy kidneys from those affected by disease. Participants will provide blood and urine samples and undergo an FFC imaging scan to assess kidney microstructure. The study seeks to determine if FFC imaging correlates with standard clinical tests and can provide insights into kidney damage that are not visible through conventional imaging methods. The innovative FFC technology allows for detailed analysis of tissue changes, potentially improving kidney disease monitoring.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and above with suspected kidney impairment or those undergoing kidney biopsies.
Not a fit: Patients with a single native kidney or those unable to safely undergo an MRI scan may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a non-invasive method for better monitoring and understanding of kidney diseases.
How similar studies have performed: Previous pilot studies have shown promising results for FFC imaging in other conditions like cancer and stroke, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: All participants: * Participants must be aged 18 and above * Participants who meet the safety criteria for undergoing an MRI scan. * Participants who can pass through a 50 cm-diameter circular hoop to ensure they will be able to fit inside the scanner * Participants must be able to give fully informed consent. * Participants must be mobile enough to be positioned onto the FFC-MRI scanner couch. Native kidney damage patients: * Patients referred for a kidney biopsy and laboratory evidence (blood tests and urine abnormalities) of kidney impairment. * Patients who are newly referred. Transplant patients: * Patients with functioning kidney transplant undergoing a kidney biopsy as a part of routine clinical care. * Patients who are newly referred. Live donors • Live kidney donors, patients investigated for potential kidney donation and deemed suitable for donation. Exclusion Criteria: Native kidney Damage Patients: * Patients with single native kidney. * Patients on dialysis. Transplant patients: • Patients with non-functioning kidney transplant. Live donors • Live donors who deemed unsuitable for kidney donation by the living kidney donation clinic. All participants: * MRI-incompatible conditions, as detected in the MRI safety screening sheet. * Participants under 18 years old. * Participants who are unable to give fully informed consent. * Women who are pregnant. * Restrictions to mobility that would prevent the correct positioning in the scanner. * Participants who suffer from claustrophobia. * Body mass index larger than 34, due to the limited bore size of the scanner. * Participants who are unable to communicate in English.
Where this trial is running
Aberdeen
- NHS Grampian — Aberdeen, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Celia G Alvarez Campano, Dr
- Email: celia.alvarezcampano@abdn.ac.uk
- Phone: +441224437828
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.